DVYSR.ST Devyser Diagnostics AB
- Market cap
- SEK 1.09B
- P/E
- 42.6x
- P/B
- 2.93x
- ROE
- 4.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DVYSR.ST undervalued?
Graham numberDVYSR.ST trades 135.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Devyser Diagnostics AB fundamental analysis
No fundamental analysis for Devyser Diagnostics AB yet.
Devyser Diagnostics AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Adv…
Full company profileDevyser Diagnostics AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Devyser Diagnostics AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 48.1M | 64.3M | 65.7M | 93.5M | 127M | 169M | 217M | 251M | 242M |
| Gross Profit | 34.8M | 52.3M | 56.6M | 74.7M | 106M | 148M | 173M | 202M | 195M |
| Operating Income | -3.51M | 8.65M | -6.96M | -21.8M | -54.9M | -56.5M | -58.3M | 10.6M | 13.1M |
| EBITDA | 1.61M | 13.3M | -6.96M | -18.1M | -46.0M | -43.8M | -26.4M | 37.7M | 42.7M |
| Net Income | 519K | 7.01M | -10.9M | -20.7M | -46.0M | -53.6M | -61.5M | -8.40M | 15.7M |
| EPS | 0.17 | 2.31 | -3.76 | -1.85 | -2.89 | -3.31 | -3.75 | -0.51 | 0.93 |
| Balance Sheet | |||||||||
| Total Assets | 48.2M | 73.7M | 74.4M | 457M | 501M | 510M | 474M | 470M | 495M |
| Total Liabilities | 18.3M | 36.7M | 43.6M | 40.2M | 69.2M | 125M | 125M | 115M | 105M |
| Shareholders' Equity | 30.0M | 37.0M | 30.8M | 417M | 431M | 385M | 349M | 354M | 390M |
| Cash & Short-term Investments | 7.54M | 10.4M | 8.34M | 378M | 364M | 263M | 145M | 77.5M | 88.7M |
| Total Debt | 9.72M | 23.9M | 21.5M | 13.0M | 21.2M | 74.8M | 59.1M | 51.9M | 44.0M |
| Cash Flow | |||||||||
| Operating Cash Flow | 6.02M | 14.6M | 627K | -16.5M | -40.5M | -69.7M | -46.8M | 8.20M | 61.9M |
| Capital Expenditure | 5.06M | 9.31M | 3.41M | 8.80M | 25.8M | 32.0M | 76.9M | 1.50M | 19.7M |
| Free Cash Flow | 957K | 5.32M | -2.79M | -25.3M | -66.3M | -102M | -124M | 6.70M | 42.1M |
| Ratios | |||||||||
| ROE | 1.7% | 18.9% | -35.5% | -5.0% | -10.7% | -13.9% | -17.6% | -2.4% | 4.0% |
| ROA | 1.1% | 9.5% | -14.7% | -4.5% | -9.2% | -10.5% | -13.0% | -1.8% | 3.2% |
| Net Profit Margin | 1.1% | 10.9% | -16.6% | -22.2% | -36.3% | -31.7% | -28.4% | -3.4% | 6.5% |
| Debt to Equity | 0.32x | 0.64x | 0.70x | 0.03x | 0.05x | 0.19x | 0.17x | 0.15x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Devyser Diagnostics AB dividends
Devyser Diagnostics AB has not paid dividends in the last 8 fiscal years.
Who owns Devyser Diagnostics AB
- Insiders 29.22%
- Institutions 45.07%
- Public & others 25.71%
- Shares outstanding 16.9M
- Free float 7.43M
Devyser Diagnostics AB company profile
- Company name
- Devyser Diagnostics AB
- Ticker
- DVYSR.ST
- ISIN
- SE0016588867
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 116
- Fiscal year end
- December
- Address
- Bränningevägen 12, Årsta, Sweden, 120 54
- Phone
- 46 8 56 21 58 50
- Website
- devyser.com
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
Devyser Diagnostics AB management
6- Mr. Jan WahlstromChief Executive Officer · born 1967
- Ms. Sabina BerlinChief Financial Officer · born 1983
- Mr. Michael Uhlin Ph.D.Chief Scientific Officer · born 1978
- Ms. Camilla WibergChief Human Resource Officer · born 1979
- Mr. John MuradVP & GM of Devyser US
- Mr. Torben TholixChief Commercial Officer